DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial.
Sundar R, Ng A, Zouridis H, Padmanabhan N, Sheng T, Zhang S, Lee MH, Ooi WF, Qamra A, Inam I, Hewitt LC, So JB, Koh V, Nankivell MG, Langley RE, Allum WH, Cunningham D, Rozen SG, Yong WP, Grabsch HI, Tan P.
Sundar R, et al. Among authors: inam i.
Eur J Cancer. 2019 Dec;123:48-57. doi: 10.1016/j.ejca.2019.09.016. Epub 2019 Oct 23.
Eur J Cancer. 2019.
PMID: 31655359
Free article.